Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models
 
Product details:

ISBN13:9789811575853
ISBN10:9811575851
Binding:Hardback
No. of pages:228 pages
Size:235x155 mm
Weight:580 g
Language:English
Illustrations: 2 Illustrations, black & white; 26 Illustrations, color; 30 Tables, color
0
Category:

Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

 
Edition number: 1st ed. 2020
Publisher: Springer
Date of Publication:
Number of Volumes: 1 pieces, Book
 
Normal price:

Publisher's listprice:
EUR 106.99
Estimated price in HUF:
44 149 HUF (42 047 HUF + 5% VAT)
Why estimated?
 
Your price:

40 617 (38 683 HUF + 5% VAT )
discount is: 8% (approx 3 532 HUF off)
The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
Click here to subscribe.
 
Availability:

Uncertain availability. Please turn to our customer service.
Can't you provide more accurate information?
 
 
Short description:

This book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways for the treatment of cancer and to develop personalized medicine.  Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.

Long description:

This book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways for the treatment of cancer and to develop personalized medicine.  Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.

Table of Contents:
Chapter 1. History of oncotherapies in cancer biology.
- Chapter 2. Electrochemical Sensors and Biosensors for the Detection of Cancer Biomarkers and Drugs.
- Chapter 3. Cell cycle arrest: An impending therapeutic strategy to curb cancer.
- Chapter 4.  Apoptotic cell death: important cellular process as chemotherapeutic target.
- Chapter 5. Regulatory roles of autophagy in cancer.
- Chapter 6. ROS and Oxidative Stress in Cancer: Recent Advances.
- Chapter 7. Inflammatory mediators: Potential drug targets in cancer.
- Chapter 8. Pharmacologic modulation of the immune response against tumours in the elderly. Chapter 9. Angiogenesis: A Therapeutic Target for Cancer.
- Chapter 10. Metastasis: A major driver of cancer pathogenesis.
- Chapter 11. Designing Personalized and Innovative Novel Drug Therapies For Cancer Treatment.